- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04704219
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (KEYNOTE-B61)
January 12, 2024 updated by: Merck Sharp & Dohme LLC
A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants With First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)
This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
152
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Macquarie Park, New South Wales, Australia, 2109
- Macquarie University-MQ Health Clinical Trials Unit ( Site 0405)
-
Waratah, New South Wales, Australia, 2298
- Calvary Mater Newcastle ( Site 0403)
-
-
Queensland
-
Brisbane, Queensland, Australia, 4029
- Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si
-
-
South Australia
-
Kurralta Park, South Australia, Australia, 5037
- Ashford Cancer Centre Research ( Site 0404)
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Monash Health ( Site 0400)
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- Fiona Stanley Hospital ( Site 0402)
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BC Cancer Vancouver-Clinical Trials Unit ( Site 1500)
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre ( Site 1501)
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Cancer Centre ( Site 1504)
-
-
Quebec
-
Québec, Quebec, Canada, G1R 3S1
- CHU de Quebec - Université Laval - Hotel Dieu de Quebec ( Site 1502)
-
-
-
-
Alsace
-
Strasbourg, Alsace, France, 67200
- Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1007)
-
-
Calvados
-
Caen, Calvados, France, 14076
- Centre François Baclesse ( Site 1000)
-
-
Languedoc-Roussillon
-
Montpellier, Languedoc-Roussillon, France, 34070
- Centre de Cancérologie du Grand Montpellier ( Site 1005)
-
-
Rhone
-
Pierre-Bénite, Rhone, France, 69310
- centre hospitalier lyon sud ( Site 1003)
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, France, 94800
- Gustave Roussy ( Site 1002)
-
-
-
-
-
Debrecen, Hungary, 4032
- Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0300)
-
-
Borsod-Abauj-Zemplen
-
Miskolc, Borsod-Abauj-Zemplen, Hungary, 3526
- Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás C
-
-
Jasz-Nagykun-Szolnok
-
Szolnok, Jasz-Nagykun-Szolnok, Hungary, 5000
- Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 0303)
-
-
Pest
-
Budapest, Pest, Hungary, 1122
- Országos Onkológiai Intézet-Urogenital Tumors Department and Clinical Pharmacology ( Site 0304)
-
-
-
-
-
Dublin, Ireland, D24 NR0A
- Tallaght University Hospital ( Site 1600)
-
-
-
-
-
Terni, Italy, 05100
- Azienda Ospedaliera Santa Maria Terni-SC Oncologia ( Site 0900)
-
-
Lazio
-
Roma, Lazio, Italy, 00168
- Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 0901)
-
-
Lombardia
-
Milan, Lombardia, Italy, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0903)
-
-
Veneto
-
Verona, Veneto, Italy, 37134
- Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma-Oncology Unit ( Site 0902)
-
-
-
-
-
Seoul, Korea, Republic of, 03722
- Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1302)
-
Seoul, Korea, Republic of, 05505
- Asan Medical Center-Department of Oncology ( Site 1300)
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center ( Site 1301)
-
-
-
-
Mazowieckie
-
Warszawa, Mazowieckie, Poland, 02-781
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
-
Warszawa, Mazowieckie, Poland, 01-748
- Luxmed Onkologia sp. z o. o. ( Site 0802)
-
-
Wielkopolskie
-
Poznań, Wielkopolskie, Poland, 60-569
- Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-chemotherapy department ( Site 0800)
-
-
-
-
-
Sankt-Peterburg, Russian Federation, 188663
- SHBI Leningrad Regional Clinical Oncology Dispensary-Clinical Trials Department ( Site 0607)
-
-
Moskva
-
Moscow, Moskva, Russian Federation, 117485
- Russian Scientific Center of Radiology-Russian Scientific Center of Radiology ( Site 0602)
-
-
Nizhegorodskaya Oblast
-
Nizhniy Novgorod, Nizhegorodskaya Oblast, Russian Federation, 603081
- Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 0605)
-
Nizhny Novgorod, Nizhegorodskaya Oblast, Russian Federation, 603074
- Volga District Medical Center-Urology Department ( Site 0604)
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0201)
-
-
Madrid, Comunidad De
-
Madrid, Madrid, Comunidad De, Spain, 28034
- Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 0200)
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Spain, 46009
- Fundación Instituto Valenciano de Oncología-Oncologico ( Site 0202)
-
-
-
-
-
Ankara, Turkey, 06100
- Ankara University Hospital Cebeci ( Site 1105)
-
Ankara, Turkey, 06230
- Hacettepe Universitesi-oncology hospital ( Site 1101)
-
Istanbul, Turkey, 34722
- Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 1103)
-
-
Istanbul
-
Istanbul- Fatih, Istanbul, Turkey, 34098
- Istanbul Universitesi Cerrahpasa ( Site 1104)
-
-
Izmir
-
Bornova, Izmir, Turkey, 35100
- Ege University Medicine of Faculty ( Site 1102)
-
-
-
-
Cherkaska Oblast
-
Cherkassy, Cherkaska Oblast, Ukraine, 18009
- Cherkasy Regional Oncology Dispensary ( Site 0504)
-
-
Chernihivska Oblast
-
Chernihiv, Chernihivska Oblast, Ukraine, 14029
- Chernihiv Medical Center of Modern Oncology ( Site 0509)
-
-
Dnipropetrovska Oblast
-
Dnipro, Dnipropetrovska Oblast, Ukraine, 49005
- Dnepropetrovsk Regional Clinical Hospital Mechnikov-Department of urology ( Site 0508)
-
-
Kharkivska Oblast
-
Kharkiv, Kharkivska Oblast, Ukraine, 61070
- CNPE "Regional Center of Oncology"-oncourology department ( Site 0502)
-
-
-
-
-
Manchester, United Kingdom, M20 4BX
- The Christie ( Site 1205)
-
-
England
-
Cambridge, England, United Kingdom, CB2 0QQ
- Cambridge University Hospital ( Site 1200)
-
-
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University Medical Center ( Site 0001)
-
-
Montana
-
Billings, Montana, United States, 59102
- St. Vincent Frontier Cancer Center ( Site 0004)
-
-
Nevada
-
Las Vegas, Nevada, United States, 89169
- Comprehensive Cancer Centers of Nevada ( Site 0010)
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center ( Site 0015)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center ( Site 0011)
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center ( Site 0008)
-
-
Washington
-
Seattle, Washington, United States, 98109
- Seattle Cancer Care Alliance ( Site 0014)
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- MEDICAL COLLEGE OF WISCONSIN ( Site 0006)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 120 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Must have a histologically-confirmed diagnosis of non-clear cell RCC.
- Has locally advanced/metastatic disease (ie, Stage IV per the American Joint Committee on Cancer).
- Has received no prior systemic therapy for advanced nccRCC. Note: Prior neoadjuvant/adjuvant therapy for nccRCC is acceptable if completed >12 months prior to allocation.
- Male participants agree to use approved contraception during the treatment period for at least 7 days after the last dose of study medication, or refrain from heterosexual intercourse during this period.
- Female participants are not pregnant or breastfeeding, and are not a woman of childbearing potential (WOCBP), OR are a WOCBP that agrees to use contraception during the treatment period and for at least 120 days post pembrolizumab, or 30 days post lenvatinib, whichever occurs last.
- Has measurable disease per RECIST 1.1 as assessed by BICR. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- Has submitted an archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.
- Has Karnofsky Performance Status (KPS) ≥70% as assessed within 10 days prior to the start of study intervention.
- Has adequately controlled blood pressure with or without antihypertensive medications
- Have adequate organ function.
Exclusion Criteria:
- Has collecting duct histology.
- A WOCBP who has a positive urine pregnancy test within 24 hours before the first dose of study intervention.
- Has a left ventricular ejection fraction below the institutional (or local laboratory) normal range.
- Has radiographic encasement or invasion of a major blood vessel, or of intratumoral cavitation.
- Has clinically significant cardiovascular disease within 12 months from first dose of study intervention.
- Has gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib.
- Has active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.
- Has had major surgery within 3 weeks prior to first dose of study intervention.
- Has received prior therapy with an anti-programmed cell-death 1 (PD-1), anti-programmed cell-death ligand 1 (PD-L1), or anti-programmed cell-death ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137).
- Has received prior systemic anticancer therapy including investigational agents within 4 weeks prior to allocation.
- Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease.
- Has received a live or attenuated vaccine within 30 days before the first dose of study intervention.
- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
- Has known active CNS metastases and/or carcinomatous meningitis.
- Has severe hypersensitivity (≥Grade 3) to pembrolizumab, lenvatinib and/or any of their excipients.
- Has an active autoimmune disease that has required systemic treatment in past 2 years
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- Has an active infection requiring systemic therapy.
- Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by local health authority.
- Has a known history of Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus.
- Has a known history of active tuberculosis (TB; Bacillus tuberculosis).
- Has had an allogenic tissue/solid organ transplant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pembrolizumab + Lenvatinib
Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation PLUS Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
|
Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation.
Other Names:
Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Up to approximately 3 years
|
Objective Response Rate (ORR) is defined as the percentage of participants with a complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors 1.1 (RECIST 1.1) by blinded independent central review (BICR).
|
Up to approximately 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR)
Time Frame: Up to approximately 4.5 years
|
Duration of Response (DOR) is defined for participants who demonstrate confirmed CR or PR as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.
|
Up to approximately 4.5 years
|
Progression-free Survival (PFS)
Time Frame: Up to approximately 4.5 years
|
Progression-free Survival (PFS) is defined as the time from the date of first dose to the first documented progressive disease (PD) per RECIST 1.1 by BICR or death from any cause, whichever occurs first.
|
Up to approximately 4.5 years
|
Overall Survival (OS)
Time Frame: Up to approximately 4.5 years
|
Overall Survival (OS) is defined as the time from date of first dose until death from any cause.
|
Up to approximately 4.5 years
|
Clinical Benefit Ratio (CBR)
Time Frame: Up to approximately 4.5 years
|
Clinical Benefit Ratio (CBR) is defined as the percentage of participants who achieved CR, PR, or stable disease (SD) for at least 6 months per RECIST 1.1 by BICR.
|
Up to approximately 4.5 years
|
Disease Control Rate (DCR)
Time Frame: Up to approximately 4.5 years
|
Disease Control Rate (DCR) is defined as the percentage of participants who achieved CR, PR, or SD per RECIST 1.1 by BICR.
|
Up to approximately 4.5 years
|
Number of Participants Who Experienced One or More Adverse Events (AEs)
Time Frame: Up to approximately 4.5 years
|
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
|
Up to approximately 4.5 years
|
Number of Participants Who Discontinued Study Medication Due to an AE
Time Frame: Up to approximately 4.5 years
|
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
|
Up to approximately 4.5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 23, 2021
Primary Completion (Estimated)
August 16, 2024
Study Completion (Estimated)
October 22, 2025
Study Registration Dates
First Submitted
January 7, 2021
First Submitted That Met QC Criteria
January 7, 2021
First Posted (Actual)
January 11, 2021
Study Record Updates
Last Update Posted (Actual)
January 16, 2024
Last Update Submitted That Met QC Criteria
January 12, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carcinoma, Renal Cell
- Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Immune Checkpoint Inhibitors
- Pembrolizumab
- Lenvatinib
Other Study ID Numbers
- 3475-B61
- MK-3475-B61 (Other Identifier: Merck)
- 2020-004087-26 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
Clinical Trials on Pembrolizumab
-
University Medical Center GroningenCompleted
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedMelanomaUnited States, France, Italy, United Kingdom, Spain, Belgium, Israel, Mexico, Japan, Canada, Netherlands, Sweden, Korea, Republic of, Australia, Russian Federation, Chile, Germany, Poland, Ireland, New Zealand, Denmark, Switzerland, South Africa
-
Merck Sharp & Dohme LLCCompletedMelanomaAustralia, South Africa, Spain, Sweden
-
Acerta Pharma BVMerck Sharp & Dohme LLCCompletedMetastatic Urothelial CarcinomaUnited States
-
HUYABIO International, LLC.Active, not recruitingNon Small Cell Lung CancerUnited States
-
Prof. Dr. Matthias PreusserUnknownPrimary Central Nervous System LymphomaAustria
-
Sichuan UniversityGeneplus-Beijing Co. Ltd.RecruitingNon-small Cell Lung CancerChina
-
Chinese University of Hong KongCompletedAcral Lentiginous MelanomaHong Kong
-
Abramson Cancer Center of the University of PennsylvaniaCompletedMalignant MelanomaUnited States